Tenofovir Disoproxil Fumarate
Bioanalytical Method Development and Validation for the Estimation of Tenofovir Disoproxil Fumarate and Lamuvidine in Human Plasma by Using Rp-Hplc.
74
ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF INVITRO DISSOLUTION STUDIES OF EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE IN PHARMACEUTICAL DOSAGE FORM BY RP-HPLC
7
Formulation and In-Vitro Evaluation of Tenofovir Disoproxil Fumarate Immediate Release Tablets.
183
FORMULATION AND EVALUATION OF SOLID DISPERSION INCLUDE FAST DISSOLVING TABLETS OF TENOFOVIR DISOPROXIL FUMARATE
18
DEVELOPMENT AND VALIDATION OF AN ANALYTICAL METHOD FOR DISSOLUTION TESTING OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE IN TABLET DOSAGE FORM BY UPLC
7
FORMULATION AND EVALUATION OF TENOFOVIR DISOPROXIL FUMARATE IMMEDIATE RELEASE TABLETS
16
Effects of Hydrochlorothiazide on Tenofovir Disoproxil Fumarate-Induced Nephrotoxicity in Rats
7
DEVELOPMENT AND VALIDATION OF STABILITY INDICATING METHOD FOR THE SIMULTANEOUS ESTIMATION OF EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE AND EFAVIRENZ IN PHARMACEUTICAL DOSAGE FORMS BY RP-HPLC
13
A NOVEL STABILITY INDICATING RP HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE DETERMINATION OF TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE IN BULK AND PHARMACEUTICAL FORMULATIONS
9
DEVELOPMENT AND VALIDATION OF RP-UPLC ANALYTICAL METHOD FOR SIMULTANEOUS ESTIMATION OF EMTRICITABINE, RILPIVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND ITS PHARMACEUTICAL DOSAGE FORMS
6
“A Stability Indicating Method for Estimating Emtricitabine and Tenofovir Disoproxil Fumarate Simultaneously in Bulk and Combined Dosage Form by UV Spectrophotometry” by Rubi Shaheen, Dr. S.H Rizwan, India.
6
APPLICATION OF QBD LIFE CYCLE APPROACH FOR STABILITY INDICATING HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF IMPURITIES IN TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE COMBINATION TABLETS
13
APPLICATIONS OF SIMULTANEOUS EQUATION METHOD FOR THE DETERMINATION OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TO DISSOLUTION STUDIES IN MARKETED TABLETSRajendra Mogal*, Madhavi shinde, Ashwini Shelke, Rahul Sable, Anil JadhavDOWNLOAD/VIEW
5
Formulation by Design (FbD) approach to develop Tenofovir Disoproxil Fumarate loaded Nanostructured Lipid Carriers (NLCs) for the aptness of nose to brain delivery
12
FORMULATION AND DEVELOPMENT OF NOVEL AND STABLE DOSAGE FORMS OF LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS BY WET GRANULATION TECHNIQUE
5
Development and Validation of RP-HPLC Method for Simultaneous Estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in Bulk and Tablet Dosage Form
6
A Precise Review on Tenofovir Disoproxil Fumarate: An Analytical Profile
15
Stability Indicating Method Development and Validation of Tenofovir Disoproxil Fumarate in Bulk and its Tablet Dosage Form by HPTLC.
8
Treatment of Chronic Hepatitis B with Tenofovir Disoproxil Fumarate in Ivory Coast
7
Simultaneous Method for Determination of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir and Cobicistat in Tablets By HPLC
5